Prosecution Insights
Last updated: November 20, 2026
Application No. 18/593,350

MAGL INHIBITORS

Non-Final OA §112
Filed
Mar 01, 2024
Priority
Sep 03, 2021 — EU 21194695.9 +1 more
Examiner
MEJIAS, SAMANTHA LEE
Art Unit
1618
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Eidgenoessische Technische Hochschule Zuerich
OA Round
1 (Non-Final)
41%
Grant Probability
Moderate
1-2
OA Rounds
1y 2m
Est. Remaining
72%
With Interview

Examiner Intelligence

Grants 41% of resolved cases
41%
Career Allowance Rate
14 granted / 34 resolved
-18.8% vs TC avg
Strong +31% interview lift
Without
With
+31.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
50 currently pending
Career history
102
Total Applications
across all art units

Statute-Specific Performance

§101
0.9%
-39.1% vs TC avg
§103
49.3%
+9.3% vs TC avg
§102
19.9%
-20.1% vs TC avg
§112
17.0%
-23.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 34 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Receipt is acknowledged of IDS filed on 07/22/2024 and 09/04/2026. Claims 1-7 and 16-20 are pending. Claims 8-15 are cancelled. Election/Restrictions Claims 1-7 and 16 allowable. Claims 17-20, previously withdrawn from consideration as a result of a restriction requirement, require all the limitations of an allowable claim. Pursuant to the procedures set forth in MPEP § 821.04(a), the restriction requirement among inventions II-IV, as set forth in the Office action mailed on 06/05/2026, is hereby withdrawn and claims 17-20 are hereby rejoined and fully examined for patentability under 37 CFR 1.104. In view of the withdrawal of the restriction requirement, applicant(s) are advised that if any claim presented in a divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See In re Ziegler, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 19 and 20 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling treatment does not reasonably provide enablement for prophylaxis, also known as preventing. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. Enablement is considered in view of the Wands factors (MPEP 2164.01 (a)). These include: (1) breadth of the claims; (2) nature of the invention; (3) state of the prior art; (4) amount of direction provided by the inventor; (5) the level of predictability in the art; (6) the existence of working examples; (7) quantity of experimentation needed to make or use the invention based on the content of the disclosure; and (8) relative skill in the art. All of the factors have been considered with regard to these claims, with the most relevant factors discussed below: 1) The breadth of claims: The instant claims are directed to a method of prophylaxis of a disorder. This is a very broad claim, one that is not supported by the instant specification. 2) The nature of the invention: The nature of the invention is prophylaxis of a disorder. Currently, there are no known agents that prevent a disorder from occurring. 3) The state of the prior art: The state of the art is very high in terms of compositions comprising a drug for the treating a disorder. However, there is no evidence in the prior art that the instant composition would prevent a disorder from occurring. 4) The amount of direction provided by the inventor: There is nothing in the specification that would indicate that the current invention prevents a disorder from occurring or reoccurring. The prevention of a disorder is a very broad claim. However, there is a substantial gap between treatment and prevention. Consequently, a burdensome amount of research would be required by one of ordinary skill in the art to bridge this gap. 5) Predictability of the art: The preventing of a disorder is highly unpredictable due to the numerous sources that could trigger a disorder. For example, a subject could be born with a disorder. The fact that being born with a disorder cannot be adjusted prior to birth that there is nothing in the prior art that could possibly prevent a disorder. 6) The presence or absence of working examples: Applicant has some examples of making the composition in the instant specification, none of which teaches how to prevent a disorder from occurring from birth. Overall, applicant fails to provide examples showing that the instant method could prevent a disorder. Therefore, the practitioner would turn to trial and error experimentations to make/use the instant compositions for preventing a disorder from the specification or the prior art. 7) The quantity of experimentation: In the instant case, there is a substantial gap between treatment and prevention. Consequently, a burdensome amount of research would be required by one of ordinary skill in the art to bridge this gap. In order to utilize the composition as claimed, the skilled artisan would be presented with an unpredictable amount of experimentation. An undetermined number of experimental factors utilizing a system for preventing a disorder would have to be resolved by the practitioner and/or the patient. The disclosure is not sufficiently discussed in the specification to provide guidance to utilize the invention as claimed. 8) The relative skill of those in the art: the skill of one of ordinary skill in the art is high, e.g. Ph.D. and M.D. level skill. In summation, Applicant does not reasonably provide enablement for preventing a disorder. Allowable Subject Matter Claims 1-7 and 16-18 are allowed. The following claim 19 drafted by the examiner and considered to distinguish patentably over the art of record in this application, is presented to applicant for consideration: A method for the treatment of a disorder in a human in need thereof, comprising administering a compound of claim 1 to the human, wherein the disorder is neuroinflammation, neurodegenerative diseases, pain, cancer, or a mental disorder. The dependent claim falls therewith. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SAMANTHA L. MEJIAS whose telephone number is (703)756-5666. The examiner can normally be reached M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, MICHAEL HARTLEY can be reached at (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /S.L.M./Examiner, Art Unit 1618 /Michael G. Hartley/Supervisory Patent Examiner, Art Unit 1618
Read full office action

Prosecution Timeline

Mar 01, 2024
Application Filed
Oct 21, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788833
METHOD FOR PRODUCING RADIOPHARMACEUTICAL AND RADIOPHARMACEUTICAL
5y 1m to grant Granted Nov 10, 2026
Patent 12778881
CILIA-TARGETING NANOPARTICLES
5y 11m to grant Granted Nov 03, 2026
Patent 12774292
LMP1 TARGETING LANTHANIDE COMPLEXES AND METHODS OF USE THEREOF
4y 4m to grant Granted Oct 27, 2026
Patent 12734260
BIOMEDICAL IMAGING OF BACTERIA AND VIRUSES
3y 10m to grant Granted Sep 15, 2026
Patent 12685790
STABLE, CONCENTRATED RADIOPHARMACEUTICAL COMPOSITION
4y 4m to grant Granted Jul 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
41%
Grant Probability
72%
With Interview (+31.0%)
3y 11m (~1y 2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 34 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month